Biogen (NASDAQ:BIIB) Releases Quarterly Earnings Results, Beats Estimates By $1.54 EPS

Key Points

• Biogen reported quarterly earnings of $5.47 per share, surpassing analysts' estimates of $3.93 by $1.54, with revenue totaling $2.65 billion, exceeding the forecast of $2.32 billion.
• The company's FY 2025 EPS guidance has been updated to between 15.500 and 16.000, reflecting positive growth expectations.
• Biogen's stock price increased by 3.1% following the earnings report, with price targets from analysts varying between $135.00 and $205.00.

Biogen (NASDAQ:BIIB - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported $5.47 EPS for the quarter, beating analysts' consensus estimates of $3.93 by $1.54, Zacks reports. Biogen had a net margin of 15.31% and a return on equity of 13.85%. The company had revenue of $2.65 billion during the quarter, compared to analyst estimates of $2.32 billion. During the same period in the prior year, the business posted $5.28 EPS. The firm's revenue was up 7.3% compared to the same quarter last year. Biogen updated its FY 2025 guidance to 15.500-16.000 EPS.

Biogen Stock Performance

Shares of BIIB traded down $3.55 on Wednesday, reaching $129.34. The company's stock had a trading volume of 1,537,891 shares, compared to its average volume of 1,573,051. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.50 and a quick ratio of 1.79. The stock has a market capitalization of $18.96 billion, a P/E ratio of 12.37, a PEG ratio of 1.04 and a beta of 0.13. The stock's 50 day simple moving average is $130.06 and its two-hundred day simple moving average is $131.64. Biogen has a 12-month low of $110.04 and a 12-month high of $207.59.

Insider Activity

In related news, insider Rachid Izzar sold 2,223 shares of the firm's stock in a transaction that occurred on Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total value of $300,105.00. Following the transaction, the insider owned 6,330 shares of the company's stock, valued at approximately $854,550. This trade represents a 25.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.18% of the company's stock.

Institutional Investors Weigh In On Biogen

An institutional investor recently raised its position in Biogen stock. Empowered Funds LLC raised its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 64.9% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,054 shares of the biotechnology company's stock after buying an additional 2,777 shares during the quarter. Empowered Funds LLC's holdings in Biogen were worth $965,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 87.93% of the company's stock.

Analyst Ratings Changes

Several research analysts recently issued reports on BIIB shares. Royal Bank Of Canada increased their price target on shares of Biogen from $208.00 to $219.00 and gave the stock an "outperform" rating in a research note on Friday, August 1st. HC Wainwright increased their price objective on shares of Biogen from $187.00 to $194.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Wall Street Zen raised shares of Biogen from a "hold" rating to a "buy" rating in a research report on Saturday. Morgan Stanley cut their price objective on shares of Biogen from $146.00 to $144.00 and set an "equal weight" rating on the stock in a research report on Friday, August 1st. Finally, Oppenheimer set a $205.00 price objective on shares of Biogen in a research report on Friday, May 2nd. Twenty-one equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $185.63.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.